Six-Year Follow Up Of Phase III Sprycel Trial Demonstrates 71 Percent Overall Survival
FDA Approves Afinitor-Aromasin Regimen For Advanced HER2-Negative Breast Cancer
Phase III Study Evaluating Halaven Fails To Meet Primary Endpoints
Upper Endoscopy Most Effective When Performed in 3-Year Intervals
Women Who Concieve Using Fertility Drugs Have a Higher Risk Of Breast Cancer Than Non-Users
Variation in Breast Density May Be Strong Risk Factor
Study: Molecular Breast Imaging Can Be As Effective as MRI
Mammography Had Limited Impact Among Swedish Women Age 40-69
High Vitamin E Consumption Can Lower Liver Cancer Risks
Gene Expression Test Accurately Classifies “Inconclusive” Samples
CAP, ASCCP Recommendations Standardize Lesion Terminology
NCI-Approved CTEP Trials For The Month of July
Trending Stories
- DOD cancer research programs face 57% funding cut in year-long continuing resolution
Pancreatic, lung, kidney cancer research programs eliminated - Kennedy announces massive cuts, centralization at HHS—NCI and FDA hit
Also this week: Columbia yields, Makary and Bhattacharya confirmed, tariffs on pharmaceuticals, and more changes impacting oncology - What Trump’s pick of RFK Jr. means for cancer: Epidemics, HPV, stunted research
Former FDA Commissioner Scott Gottlieb expresses “deep concerns” - Pediatric cancer research cut from spending legislation at last minute
Republicans quietly removed hard-won pediatric cancer bills - Jonathan Friedberg tells us how he built a cancer center in an underserved area of New York State
- The insinuation that AstroTurf causes GBM has no basis in science
The Philadelphia Inquirer series does disservice to brain tumor community
